Lantheus Holdings, Inc. (LNTH) Bundle
Understanding Lantheus Holdings, Inc. (LNTH) Revenue Streams
Understanding Lantheus Holdings, Inc. Revenue Streams
The company classifies its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Radiopharmaceutical Oncology consists of PYLARIFY and AZEDRA. In the first quarter of 2024, the company discontinued the production of AZEDRA. Precision Diagnostics includes DEFINITY, TechneLite, and other diagnostic imaging products. Strategic Partnerships and Other Revenue primarily includes out-licensing arrangements and partnerships for the company’s biomarker solutions, digital solutions, and radiotherapeutic platforms.
Revenue Breakdown by Product Category
| Product Category | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|---|---|---|---|
| PYLARIFY | $259,756 | $215,428 | $44,328 | 20.6% | $791,881 | $621,419 | $170,462 | 27.4% |
| Other Radiopharmaceutical Oncology | $0 | $848 | ($848) | (100.0%) | $384 | $2,383 | ($1,999) | (83.9%) |
| Total Radiopharmaceutical Oncology | $259,756 | $216,276 | $43,480 | 20.1% | $792,265 | $623,802 | $168,463 | 27.0% |
| DEFINITY | $76,965 | $67,336 | $9,629 | 14.3% | $231,629 | $206,688 | $24,941 | 12.1% |
| TechneLite | $20,480 | $23,272 | ($2,792) | (12.0%) | $70,380 | $65,853 | $4,527 | 6.9% |
| Other Precision Diagnostics | $6,282 | $5,740 | $542 | 9.4% | $18,039 | $17,002 | $1,037 | 6.1% |
| Total Precision Diagnostics | $103,727 | $96,348 | $7,379 | 7.7% | $320,048 | $289,543 | $30,505 | 10.5% |
| Strategic Partnerships and Other Revenue | $15,251 | $7,322 | $7,929 | 108.3% | $30,487 | $29,085 | $1,402 | 4.8% |
| Total Revenues | $378,734 | $319,946 | $58,788 | 18.4% | $1,142,800 | $942,430 | $200,370 | 21.3% |
Year-over-Year Revenue Growth Rate
The total revenues for the three months ended September 30, 2024, increased by 18.4% compared to the same period in 2023. For the nine months ended September 30, 2024, total revenues grew by 21.3% year-over-year.
Revenue Contribution by Business Segments
The primary revenue sources are driven by the following segments:
- Radiopharmaceutical Oncology: Contributed approximately 68.6% of total revenues in the three months ended September 30, 2024.
- Precision Diagnostics: Accounted for about 27.4% of total revenues in the same period.
- Strategic Partnerships and Other Revenue: Made up roughly 4.0% of total revenues.
Significant Changes in Revenue Streams
In 2024, the company experienced an increase in sales volumes of PYLARIFY and DEFINITY, which were key drivers of revenue growth. However, the cessation of AZEDRA production in early 2024 and the sale of the RELISTOR royalty rights impacted revenue from that segment significantly.
For the nine months ended September 30, 2024, revenue from PYLARIFY increased by $170,462 (27.4%) compared to the prior year, while DEFINITY also saw a $24,941 (12.1%) increase in revenue. Conversely, revenue from other radiopharmaceutical oncology products saw a decline due to discontinued operations.
The overall revenue trends indicate a strong growth trajectory primarily driven by the demand for core radiopharmaceutical products and strategic partnerships that leverage new technologies and market opportunities.
A Deep Dive into Lantheus Holdings, Inc. (LNTH) Profitability
A Deep Dive into Lantheus Holdings, Inc.'s Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross profit was $242,126 thousand, compared to $199,951 thousand for the same period in 2023. This represents a gross profit margin of approximately 64.0% for Q3 2024, up from 62.4% in Q3 2023.
For the nine months ended September 30, 2024, gross profit totaled $739,746 thousand, reflecting a significant increase from $479,674 thousand in the previous year, yielding a gross profit margin of approximately 64.7%, compared to 50.9% for the same period in 2023.
Operating Profit Margin:
Operating income for the three months ended September 30, 2024, was $133,743 thousand, leading to an operating profit margin of about 35.3%. In contrast, the operating income for the same quarter in 2023 was $112,361 thousand, resulting in an operating profit margin of 35.1%.
For the nine months ended September 30, 2024, operating income reached $343,107 thousand, with an operating profit margin of approximately 30.1%, compared to $227,156 thousand and a margin of 24.1% in the same period of 2023.
Net Profit Margin:
The net income for the three months ended September 30, 2024, was $131,093 thousand, yielding a net profit margin of approximately 34.6%. This is slightly lower than the $131,957 thousand net income and a margin of 41.2% reported for the same quarter in 2023.
For the nine months ended September 30, 2024, net income was $324,232 thousand, reflecting a net profit margin of about 28.4%, compared to $223,281 thousand and a margin of 23.7% for the previous year.
Trends in Profitability Over Time:
The following table summarizes key profitability metrics over the past two years:
| Period | Gross Profit ($ thousands) | Operating Income ($ thousands) | Net Income ($ thousands) | Gross Margin (%) | Operating Margin (%) | Net Margin (%) |
|---|---|---|---|---|---|---|
| Q3 2024 | 242,126 | 133,743 | 131,093 | 64.0% | 35.3% | 34.6% |
| Q3 2023 | 199,951 | 112,361 | 131,957 | 62.4% | 35.1% | 41.2% |
| 9M 2024 | 739,746 | 343,107 | 324,232 | 64.7% | 30.1% | 28.4% |
| 9M 2023 | 479,674 | 227,156 | 223,281 | 50.9% | 24.1% | 23.7% |
Comparison of Profitability Ratios with Industry Averages:
As of 2024, the industry average gross profit margin for companies in the biopharmaceutical sector is approximately 60%. Lantheus Holdings exceeds this average with a gross profit margin of 64.0% for Q3 2024.
The average operating margin for the industry is around 25%, which indicates that Lantheus Holdings is performing well above the industry standard with an operating margin of 35.3% for Q3 2024.
Net profit margins in the biopharmaceutical industry typically range from 15% to 25%. The company's net profit margin of 34.6% for Q3 2024 demonstrates a robust position relative to its peers.
Analysis of Operational Efficiency:
The company has shown improvements in cost management, with operating expenses increasing by 23.7% year over year for the three months ended September 30, 2024, compared to revenue growth of 18.4%. Sales and marketing expenses increased by 16.9%, while general and administrative expenses grew by 13.4%.
Research and development expenses saw a significant rise of 67.1% for the same period, reflecting a strong investment in future growth and innovation.
Overall, these metrics suggest a commitment to maintaining profitability while investing in growth initiatives, underscoring the operational efficiency of Lantheus Holdings in a competitive industry landscape.
Debt vs. Equity: How Lantheus Holdings, Inc. (LNTH) Finances Its Growth
Debt vs. Equity: How Lantheus Holdings, Inc. Finances Its Growth
Debt Levels
As of September 30, 2024, Lantheus Holdings, Inc. reported total long-term debt of $575.0 million in the form of 2.625% Convertible Senior Notes due in 2027. The company also has finance lease liabilities amounting to $1.6 million, leading to a total carrying value of long-term debt and other borrowings of $577.6 million.
The long-term debt consists solely of the Convertible Senior Notes, which were issued in December 2022. The company was required to classify the carrying value of these notes as current on the balance sheet due to recent conditions allowing for conversion.
Short-term debt is not distinctly reported; however, the current portion of long-term debt was $564.7 million.
Debt-to-Equity Ratio
The debt-to-equity ratio is a critical metric for assessing financial leverage. As of September 30, 2024, Lantheus Holdings reported total stockholders' equity of $1.179 billion. This results in a debt-to-equity ratio of approximately 0.49 (calculated as $575.0 million / $1.179 billion), indicating a balanced approach to financing relative to equity.
In comparison, the pharmaceutical industry average debt-to-equity ratio typically ranges from 0.5 to 1.0, suggesting that Lantheus is on the lower end of the scale, indicating a conservative leverage stance.
Recent Debt Issuances
In December 2022, Lantheus issued $575.0 million of Convertible Senior Notes. The net proceeds from this issuance were approximately $557.8 million after deducting discounts and offering expenses.
Additionally, the company entered into a $350.0 million revolving credit facility in December 2022, which is set to mature in December 2027.
Credit Ratings
As of the latest reports, Lantheus Holdings has not publicly disclosed specific credit ratings from major rating agencies. However, the company's financial health, including its debt levels and performance metrics, suggests a stable outlook.
Balancing Debt and Equity Funding
Lantheus Holdings maintains a strategic balance between debt financing and equity funding. The company has opted for debt instruments, such as Convertible Senior Notes, to fund growth initiatives while keeping equity dilution minimal. This approach is reflected in the recent acquisition activities and capital expenditures.
| Financial Metric | Amount (in millions) |
|---|---|
| Total Long-Term Debt | $575.0 |
| Total Stockholders' Equity | $1,179.7 |
| Debt-to-Equity Ratio | 0.49 |
| Convertible Senior Notes Issued | $575.0 |
| Revolving Credit Facility | $350.0 |
Assessing Lantheus Holdings, Inc. (LNTH) Liquidity
Assessing Lantheus Holdings, Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio is 0.93, calculated using current assets of $784.1 million and current liabilities of $844.1 million.
Quick Ratio: The quick ratio is approximately 0.67, derived from current assets excluding inventory of $70.8 million.
Analysis of Working Capital Trends
As of September 30, 2024, working capital stands at -$59.9 million, indicating potential liquidity challenges.
Cash Flow Statements Overview
Operating Cash Flow: For the nine months ended September 30, 2024, net cash provided by operating activities was $387.0 million.
Investing Cash Flow: Net cash used in investing activities during the same period was -$219.4 million, primarily due to asset acquisitions and capital expenditures.
Financing Cash Flow: Net cash used in financing activities was -$14.9 million, reflecting payments for minimum statutory tax withholding related to equity awards.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash, cash equivalents, and restricted cash totaled $868.0 million, providing a buffer against liquidity pressures.
Additionally, the company has access to a $350.0 million revolving credit facility, which enhances liquidity options.
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Current Assets | $784.1 million | $187.4 million |
| Current Liabilities | $844.1 million | $187.3 million |
| Working Capital | -$59.9 million | $0.1 million |
| Operating Cash Flow | $387.0 million | $192.9 million |
| Investing Cash Flow | -$219.4 million | $18.0 million |
| Financing Cash Flow | -$14.9 million | -$12.6 million |
| Cash and Cash Equivalents | $868.0 million | $615.7 million |
| Revolving Credit Facility | $350.0 million | N/A |
Is Lantheus Holdings, Inc. (LNTH) Overvalued or Undervalued?
Valuation Analysis
To assess whether the company is overvalued or undervalued, we will explore key financial ratios, stock price trends, dividend policies, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current P/E ratio stands at 17.8, calculated from a recent stock price of $84.00 and earnings per share (EPS) of $4.69.
Price-to-Book (P/B) Ratio
The P/B ratio is reported at 5.7, with a book value per share of approximately $14.67.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is recorded at 15.2, based on an enterprise value of $1.45 billion and EBITDA of $95.5 million.
Stock Price Trends
Over the past 12 months, the stock has exhibited the following price trends:
| Month | Closing Price | Change (%) |
|---|---|---|
| October 2023 | $84.00 | +12.5% |
| September 2023 | $74.67 | +8.2% |
| August 2023 | $69.00 | +5.0% |
| July 2023 | $65.71 | -1.5% |
| June 2023 | $66.72 | +3.1% |
| May 2023 | $64.62 | -4.0% |
| April 2023 | $67.00 | +2.5% |
Dividend Yield and Payout Ratios
The company currently does not pay any dividends, and thus the dividend yield is 0%. The payout ratio is also 0% as no dividends are declared.
Analyst Consensus
Analyst consensus ratings indicate a majority hold rating:
- Buy: 5 analysts
- Hold: 12 analysts
- Sell: 2 analysts
These insights provide a comprehensive overview of the company's valuation metrics, stock price performance, and market sentiment, useful for investors evaluating its financial health.
Key Risks Facing Lantheus Holdings, Inc. (LNTH)
Key Risks Facing Lantheus Holdings, Inc.
The financial health of Lantheus Holdings, Inc. is influenced by several internal and external risk factors that could impact its operations and profitability. Below is an analysis of these key risks.
Industry Competition
The competitive landscape in the pharmaceutical and biotechnology sector is intense. The company faces competition from both established firms and emerging biotech companies. For instance, Lantheus Holdings reported total revenues of $378.7 million for the three months ended September 30, 2024, up from $319.9 million in the same period in 2023, indicating growth but also highlighting the need to maintain competitive advantages.
Regulatory Changes
Regulatory risk remains a significant concern, as the company must comply with stringent FDA regulations. Recent changes in income tax disclosure requirements, effective after December 15, 2024, may require additional resources to ensure compliance. Additionally, the company has a $30.3 million surety bond in place to provide financial assurance for potential decommissioning of its production facility.
Market Conditions
Market conditions can significantly impact sales and revenue growth. For example, the transition in sales revenue from the discontinued product AZEDRA led to a decrease in royalties, affecting overall revenue streams. The sales of PYLARIFY and DEFINITY have been strong, contributing to a revenue increase of 21.3% year-over-year.
Operational Risks
The company has faced operational challenges, including the discontinuation of AZEDRA manufacturing, which may impact cash flow and operational efficiency. The impairment charge of $15.6 million in research and development expenses related to AZEDRA also highlights operational risks.
Financial Risks
Financial risks are evident in the company’s capital structure. The conditional conversion feature of the $575 million convertible senior notes due 2027 may adversely affect liquidity if triggered. As of September 30, 2024, the carrying value of the company's convertible debt was $575 million, with an estimated fair value of $892.4 million.
Strategic Risks
Strategic risks include the potential for unsuccessful product launches and the company’s reliance on key products for revenue generation. The recent acquisition of Meilleur for investigational use of NAV-4694 is a strategic move, but such acquisitions can carry risks of integration and market acceptance.
Mitigation Strategies
To mitigate these risks, the company is investing in expanding its sales and marketing efforts, particularly for PYLARIFY, with an increase in sales and marketing expenses by $27.8 million for the nine months ended September 30, 2024. Additionally, ongoing assessments of regulatory compliance and market strategy adjustments are critical for sustaining growth.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Intense competition from established firms and emerging biotech companies. | Revenue growth of $378.7 million in Q3 2024 |
| Regulatory Changes | Stricter compliance required with new FDA regulations and tax disclosures. | Financial assurance bond of $30.3 million |
| Market Conditions | Impact of market fluctuations on sales and revenue streams. | Revenue increase of 21.3% year-over-year |
| Operational Risks | Challenges from discontinuation of products and operational efficiency. | Impairment charge of $15.6 million for AZEDRA |
| Financial Risks | Risks associated with the convertible debt structure and liquidity. | Convertible debt carrying value of $575 million |
| Strategic Risks | Risks from product launches and reliance on key products. | Acquisition of Meilleur for NAV-4694 development |
Future Growth Prospects for Lantheus Holdings, Inc. (LNTH)
Growth Opportunities
Future growth prospects for Lantheus Holdings, Inc. are bolstered by several key drivers, including product innovations, market expansions, and strategic partnerships.
Key Growth Drivers
- Product Innovations: The company's flagship product, PYLARIFY, generated revenues of $259.8 million for the three months ended September 30, 2024, a growth of 20.6% from the prior year. PYLARIFY's total revenue for the nine months ended September 30, 2024, reached $791.9 million, up 27.4% year-over-year .
- Market Expansions: The acquisition of Meilleur Technologies in June 2024 introduced revenue from the investigational use of NAV-4694, contributing to overall revenue growth .
- Acquisitions: The company made significant investments, including a payment of $28.0 million for exclusive options and rights related to new therapeutic candidates .
Future Revenue Growth Projections
The total revenues for the nine months ended September 30, 2024, were $1.14 billion, reflecting a year-over-year increase of 21.3% from $942.4 million in the same period of 2023 . Analysts project continued growth driven by the increasing adoption of PYLARIFY and the launch of new diagnostic products.
Strategic Initiatives and Partnerships
- Partnerships: The ongoing collaboration with Perspective and the acquisition of rights to innovative therapies are expected to enhance the product pipeline and market reach .
- Sales Expansion: Increased investment in the sales force for PYLARIFY, which includes expanding the marketing team, is projected to drive further revenue increases .
Competitive Advantages
Lantheus holds a competitive edge through its well-established brand recognition in the oncology imaging market, particularly with PYLARIFY. The company currently has the largest dedicated commercial team in the PSMA PET imaging space . This strategic positioning, combined with innovative product offerings, enhances its potential for sustained growth.
| Key Metrics | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenues | $378.7 million | $319.9 million | $58.8 million | 18.4% |
| PYLARIFY Revenue | $259.8 million | $215.4 million | $44.3 million | 20.6% |
| Gross Profit | $242.1 million | $200.0 million | $42.2 million | 21.1% |
| Net Income | $131.1 million | $132.0 million | ($0.9 million) | (0.7%) |
In summary, the combination of innovative product development, strategic acquisitions, and expanding market presence positions Lantheus for substantial growth in the coming years. The company's ability to leverage its competitive advantages will be crucial in navigating the evolving healthcare landscape.
Lantheus Holdings, Inc. (LNTH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Lantheus Holdings, Inc. (LNTH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Lantheus Holdings, Inc. (LNTH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Lantheus Holdings, Inc. (LNTH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.